We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

AIDIAN

Aidian, formerly Orion Diagnostica, is a Finnish-based IVD company with almost 50 years of experience in developing a... read more Featured Products: More products

Download Mobile App





Orion Diagnostica Showcases Range of Products in Anaheim

By LabMedica International staff writers
Posted on 05 Aug 2019
Orion Diagnostica (Espoo, Finland) showcased its FDA-cleared QuikRead go CRP along with other QuikRead go products at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo held in Anaheim, California, USA, from August 6-8.

Orion Diagnostica specializes in accurate and affordable clinical diagnostic and hygiene monitoring tests. More...
It focuses on point-of-care diagnostic tools that enable healthcare professionals to detect diseases more quickly, make evidence-based diagnoses and treatment decisions, and follow up on treatment outcomes. Orion Diagnostica’s QuikRead go CRP test is an immunoturbidimetric assay for the in vitro quantitative determination of C-reactive protein (CRP) in K2-EDTA and lithium heparin whole blood, K2-EDTA and lithium heparin plasma, and in serum samples.

The test is carried out by means of the company’s QuikRead go instrument, a compact, automatic system that can be connected to HIS/LIS systems. The QuikRead go makes it easy to add patient and/or operator identification information together with the result which is automatically stored in the instrument’s internal memory. Its intuitive user interface enables a variety of settings to be personalized and the instrument can be easily combined with accessories, such as a barcode reader and a printer.

At AACC 2019, Orion Diagnostica also showcased its Hygicult and Easicult products for hygiene monitoring. Orion Diagnostica’s Easicult products are easy to use culture tests intended for monitoring microbial contaminations in industrial fluids. Using Easicult does not require any microbiological expertise, advance preparation or equipment and the slides can easily be used on-site. The test slides can be used as convenient transport media if further analysis of the samples is needed. Similarly, the company’s Hygicult product line comprises of a selection of dipslide culture tests, which are designed for reliable, economic and timesaving on-site microbial detection, especially on surfaces. The slides can also be used as convenient transport media for cultured samples.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Thyroid Test
Anti-Thyroid EIA Test
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.